Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 1:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Miami, Florida Clear all
Terminated Phase 2 Interventional

Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects

NCT00498914
View directory record Official record
Conditions
Lymphoma, Large-Cell, Diffuse, Lymphoma, B-Cell Refractory
Interventions
YM155
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
12
States / cities
Beverly Hills, California • Palo Alto, California • Aurora, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2015 · Synced Jul 24, 2026, 1:07 AM EDT
Active, not recruiting Phase 2 Interventional

Conditioning SCID Infants Diagnosed Early

NCT03619551
View directory record Official record
Conditions
SCID
Interventions
Busulfan, Cell processing for TCRαβ+/CD19+ depletion
Drug · Device
Lead sponsor
Center for International Blood and Marrow Transplant Research
Network
Eligibility
0 Years to 2 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
40
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Jul 24, 2026, 1:07 AM EDT
Completed Phase 2 Interventional Results available

Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis

NCT03451045
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Lenabasum 20 mg, Lenabasum 5 mg, Placebo
Drug · Other
Lead sponsor
Corbus Pharmaceuticals Inc.
Industry
Eligibility
12 Years and older
Enrollment
447 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
34
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Long Beach, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2023 · Synced Jul 24, 2026, 1:07 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Randomized, Double Blind, Parallel Group, Placebo Controlled, Multicenter Outpatient Trial Of PD 0200390 In Adults With Primary Insomnia

NCT00569972
View directory record Official record
Conditions
Insomnia
Interventions
PD 0200390, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 64 Years
Enrollment
682 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
71
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 57 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2012 · Synced Jul 24, 2026, 1:07 AM EDT
Recruiting Phase 2 Interventional

A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC)

NCT05307939
View directory record Official record
Conditions
HPV, Oropharynx Cancer, HPV-Related Carcinoma, HPV-Related Malignancy, HPV Positive Oropharyngeal Squamous Cell Carcinoma
Interventions
HPV ctDNA Assay, MRI Studies, EORTC QLQ H&N 35 and C30, MDADI-HN, COST-FACIT, Intensity-Modulated Radiation Therapy (Arm A), Chemoradiation (Arm B)
Diagnostic Test · Behavioral · Radiation + 1 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
8
States / cities
Miami, Florida • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Jul 24, 2026, 1:07 AM EDT
Completed Phase 2 Interventional Results available

S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin

NCT00234039
View directory record Official record
Conditions
Bladder Cancer
Interventions
gemcitabine hydrochloride
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 120 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
98
States / cities
Little Rock, Arkansas • Los Angeles, California • Leesburg, Florida + 56 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2016 · Synced Jul 24, 2026, 1:07 AM EDT
Terminated Phase 4 Interventional Results available

A Study of Arformoterol Tartrate Inhalation Solution and Tiotropium Bromide on Re-hospitalization in Chronic Obstructive Pulmonary Disease (COPD) Subjects

NCT02275481
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Arformoterol tartrate inhalation solution, Tiotropium
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
55 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
28
States / cities
Birmingham, Alabama • Flagstaff, Arizona • Waterbury, Connecticut + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2018 · Synced Jul 24, 2026, 1:07 AM EDT
Completed No phase listed Observational

Characteristics and Disease Progression of Mixed Connective Tissue Disease and Systemic Lupus Erythematosus

NCT00582881
View directory record Official record
Conditions
Mixed Connective Tissue Disease (MCTD), Systemic Lupus Erythematosus (SLE)
Interventions
Not listed
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 100 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2025
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Jul 24, 2026, 1:07 AM EDT
Completed Not applicable Interventional Results available

Improving Satisfaction, Engagement and Outcomes Among Traditionally Underserved Children Through Cultural Formulation

NCT03499600
View directory record Official record
Conditions
Disruptive Behavior
Interventions
Clinical Assessment and CFI, Clinical Assessment
Behavioral
Lead sponsor
Florida International University
Other
Eligibility
2 Years to 7 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 6, 2023 · Synced Jul 24, 2026, 1:07 AM EDT
Completed Phase 4 Interventional Results available

Efficacy and Tolerability of Armodafinil in Adults With Excessive Sleepiness Associated With Shift Work Disorder

NCT01080807
View directory record Official record
Conditions
Excessive Sleepiness
Interventions
Armodafinil, Matching Placebo
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 65 Years
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
63
States / cities
Phoenix, Arizona • Tucson, Arizona • Hot Springs, Arkansas + 56 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2012 · Synced Jul 24, 2026, 1:07 AM EDT
Recruiting Phase 2 Interventional

A Study to Assess the Effectiveness and Safety of GSK3862995B in Adults With Bronchiectasis

NCT07201051
View directory record Official record
Conditions
Bronchiectasis
Interventions
GSK3862995B, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 85 Years
Enrollment
446 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
14
States / cities
Mobile, Alabama • La Palma, California • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Jul 24, 2026, 1:07 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies

NCT02963831
View directory record Official record
Conditions
Colorectal Cancer, Ovarian Cancer, Appendiceal Cancer
Interventions
ONCOS-102, Durvalumab, Cyclophosphamide
Biological · Drug
Lead sponsor
Ludwig Institute for Cancer Research
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
6
States / cities
San Diego, California • Miami, Florida • Buffalo, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2022 · Synced Jul 24, 2026, 1:07 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Amantadine Hydrochloride (HCl) ER Tablets to Treat Parkinson's Disease Patients With LID.

NCT02153645
View directory record Official record
Conditions
Parkinson's Disease, Levodopa Induced Dyskinesias (LID)
Interventions
240mg Amantadine HCl ER tablets, Placebo tablets, 320mg Amantadine HCl ER tablets
Drug
Lead sponsor
Adamas Pharmaceuticals, Inc.
Industry
Eligibility
30 Years to 85 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
26
States / cities
Tucson, Arizona • Fountain Valley, California • Irvine, California + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2022 · Synced Jul 24, 2026, 1:07 AM EDT
Completed Phase 1 Interventional

RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma

NCT00101972
View directory record Official record
Conditions
Cancer
Interventions
monoclonal antibody RAV12
Biological
Lead sponsor
MacroGenics
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
5
States / cities
Santa Monica, California • Washington D.C., District of Columbia • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2022 · Synced Jul 24, 2026, 1:07 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

CircaHealth Development and Evaluation

NCT03835572
View directory record Official record
Conditions
Health Behavior, Health Knowledge, Attitudes, Practice, Circadian Rhythm
Interventions
CircaHealth: a course on circadian rhythms and health, Sleep hygiene materials
Other
Lead sponsor
University of Miami
Other
Eligibility
Not listed
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 8, 2019 · Synced Jul 24, 2026, 1:07 AM EDT
Completed Phase 2 Interventional Results available

Study of CVN424 in Parkinson's Disease Patients With Motor Fluctuations

NCT04191577
View directory record Official record
Conditions
Parkinson Disease
Interventions
CVN424 Low Dose, CVN424 High Dose, Placebo
Drug
Lead sponsor
Cerevance Beta, Inc.
Industry
Eligibility
30 Years to 80 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
21
States / cities
Long Beach, California • Pasadena, California • Boca Raton, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2024 · Synced Jul 24, 2026, 1:07 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

OAB and the Microbiome

NCT04831801
View directory record Official record
Conditions
Overactive Bladder, Urgency-frequency Syndrome
Interventions
Not listed
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
2
States / cities
Fort Lauderdale, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 20, 2024 · Synced Jul 24, 2026, 1:07 AM EDT
Completed Phase 2 Interventional Results available

Sofosbuvir Plus Ribavirin, or Ledipasvir/Sofosbuvir in Adults With HCV Infection and Renal Insufficiency

NCT01958281
View directory record Official record
Conditions
HCV Infection
Interventions
SOF, RBV, LDV/SOF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
7
States / cities
San Francisco, California • Miami, Florida • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2018 · Synced Jul 24, 2026, 1:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and Pharmacokinetics of EQU-001 in Healthy Volunteers

NCT05004571
View directory record Official record
Conditions
Safety Issues
Interventions
EQU-001, Placebo
Drug
Lead sponsor
Equilibre Biopharmaceuticals B.V.
Industry
Eligibility
18 Years to 65 Years
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Hialeah, Florida
Source: ClinicalTrials.gov public record
Updated Jan 31, 2023 · Synced Jul 24, 2026, 1:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetic Study of Omaveloxolone in Subjects With Hepatic Impairment and Normal Hepatic Function

NCT03902002
View directory record Official record
Conditions
Hepatic Impairment
Interventions
Omaveloxolone 50 mg capsules
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 70 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
3
States / cities
Tustin, California • Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Jul 24, 2026, 1:07 AM EDT
Recruiting Phase 4 Interventional

Phase 4 Study: Long-term Safety and Efficacy of NT-501 in MacTel Type 2, Including Sham Procedure Participants

NCT06971939
View directory record Official record
Conditions
Macular Telangiectasia Type 2 (MacTel)
Interventions
NT-501/revakinagene taroretcel-lwey
Combination Product
Lead sponsor
Neurotech Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
23
States / cities
La Jolla, California • Los Angeles, California • Palo Alto, California + 19 more
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Jul 24, 2026, 1:07 AM EDT
Terminated Phase 2 Interventional Results available

HORIZON: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005

NCT04566445
View directory record Official record
Conditions
Dry Age-related Macular Degeneration
Interventions
GT005
Drug
Lead sponsor
Gyroscope Therapeutics Limited
Industry
Eligibility
55 Years and older
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
45
States / cities
Phoenix, Arizona • Beverly Hills, California • Fullerton, California + 41 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Jul 24, 2026, 1:07 AM EDT
Completed No phase listed Observational

A Client-Based Outcome System for Individuals With Lower Limb Amputation

NCT01750372
View directory record Official record
Conditions
Amputation
Interventions
Not listed
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
1,572 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
2
States / cities
Miami, Florida • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 17, 2016 · Synced Jul 24, 2026, 1:07 AM EDT
Completed Phase 2 Interventional

Dose-Response of Adenosine for Perioperative Pain

NCT00298636
View directory record Official record
Conditions
Perioperative Pain
Interventions
adenosine
Drug
Lead sponsor
Xsira Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
8
States / cities
San Francisco, California • Miami, Florida • Augusta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2006 · Synced Jul 24, 2026, 1:07 AM EDT